Intra-ovarian injection of platelet-rich plasma in patients with premature ovarian insufficiency

Not Applicable

Recruiting

• Conditions: Premature ovarian insufficiency.; Female infertility, unspecified; N97.9

• Registration Number: IRCT20080831001141N41
• Lead Sponsor: ROYAN Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 54

Inclusion Criteria

Patients with premature ovarian insufficiency according to european society of human reproduction and embryology (ESHRE) guideline
Body mass index < 35 Kg/m2
Normal karyotype
Normal fragile X messenger ribonucleoprotein 1 (FMR1) gene

Exclusion Criteria

Endocrine, hematologic and autoimmune disorders
Chromosomal and genetic abnormalities
Cancer history
Uterine anomalies
Sever adenomyosis
Endometriosis
Hydrosalpinx
Uterine fibromatosis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of follicle-stimulating hormone (FSH). Timepoint: 6-8 weeks after intra-ovarian injection of platelet-rich plasma. Method of measurement: Blood test.;Serum level of anti-mullerian hormone (AMH). Timepoint: 6-8 weeks after intra-ovarian injection of platelet-rich plasma. Method of measurement: Blood test.